Ascendis Secures Global Settlement with BioMarin for YUVIWEL®, Clearing Path for Commercialization
Event summary
- Ascendis Pharma and BioMarin have entered a binding term sheet for a global settlement and license agreement related to YUVIWEL® (navepegritide), resolving all litigation and disputes between the companies.
- BioMarin grants Ascendis a non-exclusive, worldwide, royalty-bearing license for navepegritide-related products, with royalty payments of 20% in the U.S. and 18% in the EU, South Korea, and Brazil until May 20, 2030.
- Ascendis expects to generate more than €500 million in operating cash flow in 2026 and aims for €5 billion in revenue by 2030.
- YUVIWEL® was approved by the FDA in February 2026 and is under review by the European Medicines Agency, with a regulatory decision anticipated in Q4 2026.
The big picture
This settlement removes a significant legal overhang for Ascendis, allowing it to focus on commercializing YUVIWEL® without regulatory or litigation constraints. The deal underscores the strategic importance of navepegritide in treating achondroplasia, a niche but high-unmet-need market. Ascendis' ambitious revenue targets will hinge on its ability to navigate royalty payments while expanding market reach, particularly in the EU and other key regions.
What we're watching
- Commercialization Pace
- How quickly Ascendis can scale YUVIWEL® commercialization post-settlement, given the rapid uptake in the U.S. and pending EU approval.
- Revenue Targets
- Whether Ascendis can sustain its projected €5 billion revenue by 2030, considering the royalty obligations to BioMarin.
- Regulatory Timing
- The pace at which the European Medicines Agency will approve YUVIWEL®, which could impact Ascendis' near-term commercialization strategy.